The Center for Precision Medicine Multi-omics Research (CPMMR) was officially launched in June 2018 with the support of “Double First-Class” funding. CPMMR is directly affiliated to Peking University Health Science Center. Professor Catherine CL Wong serves as the director of the center. The center focuses on the clinical and biomedical research. Through the intersection of clinical medicine, innovative technology and basic research, the center aims to provide the new direction to solve clinical and biomedical problems.
CPMMR is a center integrating basic research, academic exchanges and translation of scientific technological achievements. Under the national policy of “Healthy China”, the core mission of the center is to establish innovative and rigorous biomarker discovery and verification methodology for accurate disease classification, diagnosis and mechanism, for in-depth exploration of disease risk factors, as well as the implementation of precision medicine for clinical applications. The goal is to become the leading research organization on precision medicine in China and even in the world.
Taking important clinical questions as the root, the center utilizes cutting-edge high-throughput multi-omics technologies (including transcriptomics, proteomics, metabonomics, PTMs and microbiology) and informatics analysis, combined with clinical data to establish a platform for the discovery, functional validation and standardization of specialized clinical biomarkers including early screening, diagnosis, treatment efficacy assessment and drug targets), which ultimately can be used in the clinical tests.
We envision this would achieve the true personalized diagnosis and targeted treatment based on molecular characteristics and would bring high quality and more cost-effective health care to our society.